Given the druggable nature of ERRγ and the availability of multiple potent ERRγ antagonists (Chao et al, 2006; Singh et al, 2019), our findings are likely to contribute to the development of new therapeutic strategies for advanced SCLC. Here, ESRRG is linked to small cell lung carcinoma.